Hsbc Holdings PLC Takes Position in Ingevity Corporation $NGVT

Hsbc Holdings PLC bought a new position in Ingevity Corporation (NYSE:NGVT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 20,925 shares of the company’s stock, valued at approximately $1,568,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Assetmark Inc. increased its holdings in Ingevity by 9.6% in the 1st quarter. Assetmark Inc. now owns 1,584 shares of the company’s stock valued at $113,000 after acquiring an additional 139 shares during the last quarter. Advisory Services Network LLC lifted its position in shares of Ingevity by 4.4% in the third quarter. Advisory Services Network LLC now owns 6,947 shares of the company’s stock worth $383,000 after buying an additional 293 shares in the last quarter. Amundi raised its holdings in shares of Ingevity by 4.8% during the 3rd quarter. Amundi now owns 6,626 shares of the company’s stock worth $364,000 after acquiring an additional 302 shares in the last quarter. Isthmus Partners LLC raised its holdings in shares of Ingevity by 0.5% during the 4th quarter. Isthmus Partners LLC now owns 72,245 shares of the company’s stock worth $4,275,000 after acquiring an additional 375 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its holdings in shares of Ingevity by 85.8% in the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after purchasing an additional 387 shares in the last quarter. Institutional investors own 91.59% of the company’s stock.

Ingevity Stock Performance

Ingevity stock opened at $69.48 on Tuesday. The company has a debt-to-equity ratio of 22.52, a current ratio of 1.61 and a quick ratio of 1.15. Ingevity Corporation has a 1-year low of $45.85 and a 1-year high of $79.29. The firm has a market capitalization of $2.39 billion, a P/E ratio of 47.27 and a beta of 1.16. The company’s 50-day moving average is $73.47 and its 200 day moving average is $71.76.

Ingevity (NYSE:NGVT) last announced its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.41. The business had revenue of $314.10 million during the quarter, compared to analyst estimates of $312.20 million. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Research analysts forecast that Ingevity Corporation will post 5.4 EPS for the current year.

Analyst Ratings Changes

NGVT has been the topic of a number of recent research reports. Weiss Ratings raised shares of Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, July 31st. Wall Street Zen downgraded shares of Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 1st. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $80.00.

Insider Buying and Selling

In related news, CEO David H. Li sold 5,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $75.83, for a total transaction of $379,150.00. Following the completion of the transaction, the chief executive officer owned 120,636 shares in the company, valued at $9,147,827.88. The trade was a 3.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ryan C. Fisher sold 2,709 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $73.72, for a total value of $199,707.48. Following the completion of the transaction, the senior vice president directly owned 15,722 shares in the company, valued at $1,159,025.84. This trade represents a 14.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 17,801 shares of company stock valued at $1,347,481 over the last three months. 0.88% of the stock is owned by corporate insiders.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.